Post-event Feedback Survey

Thank you for attending the MPE 10th Anniversary and Masterclass 2021! Your feedback will help us to improve your experience at future events.

Question Title

* 1. I am a

MPE Member

Patient

Advocate

Carer

Health Care Professional

Pharmaceutical industry representative

Other

Question Title

* 2. How relevant were the event sessions to you on Friday, July 2?

	Extremely relevant	Very relevant	Somewhat relevant	Not so relevant	Not at all relevant	N/A
Early detection and diagnosis of MGUS and SMM María-Victoria Mateos	Early detection and diagnosis of MGUS and SMM María-Victoria Mateos Extremely relevant	Early detection and diagnosis of MGUS and SMM María-Victoria Mateos Very relevant	Early detection and diagnosis of MGUS and SMM María-Victoria Mateos Somewhat relevant	Early detection and diagnosis of MGUS and SMM María-Victoria Mateos Not so relevant	Early detection and diagnosis of MGUS and SMM María-Victoria Mateos Not at all relevant	Early detection and diagnosis of MGUS and SMM María-Victoria Mateos N/A
New developments and controversies in myeloma Mohamad Mohty	New developments and controversies in myeloma Mohamad Mohty Extremely relevant	New developments and controversies in myeloma Mohamad Mohty Very relevant	New developments and controversies in myeloma Mohamad Mohty Somewhat relevant	New developments and controversies in myeloma Mohamad Mohty Not so relevant	New developments and controversies in myeloma Mohamad Mohty Not at all relevant	New developments and controversies in myeloma Mohamad Mohty N/A
COVID-19 and its effect on myeloma and AL amyloidosis patients Mohamad Mohty	COVID-19 and its effect on myeloma and AL amyloidosis patients Mohamad Mohty Extremely relevant	COVID-19 and its effect on myeloma and AL amyloidosis patients Mohamad Mohty Very relevant	COVID-19 and its effect on myeloma and AL amyloidosis patients Mohamad Mohty Somewhat relevant	COVID-19 and its effect on myeloma and AL amyloidosis patients Mohamad Mohty Not so relevant	COVID-19 and its effect on myeloma and AL amyloidosis patients Mohamad Mohty Not at all relevant	COVID-19 and its effect on myeloma and AL amyloidosis patients Mohamad Mohty N/A
MPE members' resiliency during COVID-19 Emilia Demczur and Varda Shoham	MPE members' resiliency during COVID-19 Emilia Demczur and Varda Shoham Extremely relevant	MPE members' resiliency during COVID-19 Emilia Demczur and Varda Shoham Very relevant	MPE members' resiliency during COVID-19 Emilia Demczur and Varda Shoham Somewhat relevant	MPE members' resiliency during COVID-19 Emilia Demczur and Varda Shoham Not so relevant	MPE members' resiliency during COVID-19 Emilia Demczur and Varda Shoham Not at all relevant	MPE members' resiliency during COVID-19 Emilia Demczur and Varda Shoham N/A

Comment

Question Title

* 3. Was the content of the sessions on July 2 easy to understand?

	Extremely easy to understand	Very easy to understand	Somewhat easy to understand	Not so easy to understand	Not at all easy to understand	N/A
Early detection and diagnosis of MGUS and SMM María-Victoria Mateos	Early detection and diagnosis of MGUS and SMM María-Victoria Mateos Extremely easy to understand	Early detection and diagnosis of MGUS and SMM María-Victoria Mateos Very easy to understand	Early detection and diagnosis of MGUS and SMM María-Victoria Mateos Somewhat easy to understand	Early detection and diagnosis of MGUS and SMM María-Victoria Mateos Not so easy to understand	Early detection and diagnosis of MGUS and SMM María-Victoria Mateos Not at all easy to understand	Early detection and diagnosis of MGUS and SMM María-Victoria Mateos N/A
New developments and controversies in myeloma Mohamad Mohty	New developments and controversies in myeloma Mohamad Mohty Extremely easy to understand	New developments and controversies in myeloma Mohamad Mohty Very easy to understand	New developments and controversies in myeloma Mohamad Mohty Somewhat easy to understand	New developments and controversies in myeloma Mohamad Mohty Not so easy to understand	New developments and controversies in myeloma Mohamad Mohty Not at all easy to understand	New developments and controversies in myeloma Mohamad Mohty N/A
COVID-19 and its effect on myeloma and AL amyloidosis patients Mohamad Mohty	COVID-19 and its effect on myeloma and AL amyloidosis patients Mohamad Mohty Extremely easy to understand	COVID-19 and its effect on myeloma and AL amyloidosis patients Mohamad Mohty Very easy to understand	COVID-19 and its effect on myeloma and AL amyloidosis patients Mohamad Mohty Somewhat easy to understand	COVID-19 and its effect on myeloma and AL amyloidosis patients Mohamad Mohty Not so easy to understand	COVID-19 and its effect on myeloma and AL amyloidosis patients Mohamad Mohty Not at all easy to understand	COVID-19 and its effect on myeloma and AL amyloidosis patients Mohamad Mohty N/A
MPE members' resiliency during COVID-19 Emilia Demczur and Varda Shoham	MPE members' resiliency during COVID-19 Emilia Demczur and Varda Shoham Extremely easy to understand	MPE members' resiliency during COVID-19 Emilia Demczur and Varda Shoham Very easy to understand	MPE members' resiliency during COVID-19 Emilia Demczur and Varda Shoham Somewhat easy to understand	MPE members' resiliency during COVID-19 Emilia Demczur and Varda Shoham Not so easy to understand	MPE members' resiliency during COVID-19 Emilia Demczur and Varda Shoham Not at all easy to understand	MPE members' resiliency during COVID-19 Emilia Demczur and Varda Shoham N/A

Comment

Question Title

* 4. How relevant were the event sessions to you on Saturday, July 3?

	Extremely relevant	Very relevant	Somewhat relevant	Not so relevant	Not at all relevant	N/A
Developments in AL amyloidosis Monique Minnema	Developments in AL amyloidosis Monique Minnema Extremely relevant	Developments in AL amyloidosis Monique Minnema Very relevant	Developments in AL amyloidosis Monique Minnema Somewhat relevant	Developments in AL amyloidosis Monique Minnema Not so relevant	Developments in AL amyloidosis Monique Minnema Not at all relevant	Developments in AL amyloidosis Monique Minnema N/A
Myeloma related diseases Paolo Milani	Myeloma related diseases Paolo Milani Extremely relevant	Myeloma related diseases Paolo Milani Very relevant	Myeloma related diseases Paolo Milani Somewhat relevant	Myeloma related diseases Paolo Milani Not so relevant	Myeloma related diseases Paolo Milani Not at all relevant	Myeloma related diseases Paolo Milani N/A
Immunotherapy in the treatment of myeloma and AL amyloidosis María-Victoria Mateos	Immunotherapy in the treatment of myeloma and AL amyloidosis María-Victoria Mateos Extremely relevant	Immunotherapy in the treatment of myeloma and AL amyloidosis María-Victoria Mateos Very relevant	Immunotherapy in the treatment of myeloma and AL amyloidosis María-Victoria Mateos Somewhat relevant	Immunotherapy in the treatment of myeloma and AL amyloidosis María-Victoria Mateos Not so relevant	Immunotherapy in the treatment of myeloma and AL amyloidosis María-Victoria Mateos Not at all relevant	Immunotherapy in the treatment of myeloma and AL amyloidosis María-Victoria Mateos N/A
A clinical perspective on access in central and eastern Europe Roman Hájek	A clinical perspective on access in central and eastern Europe Roman Hájek Extremely relevant	A clinical perspective on access in central and eastern Europe Roman Hájek Very relevant	A clinical perspective on access in central and eastern Europe Roman Hájek Somewhat relevant	A clinical perspective on access in central and eastern Europe Roman Hájek Not so relevant	A clinical perspective on access in central and eastern Europe Roman Hájek Not at all relevant	A clinical perspective on access in central and eastern Europe Roman Hájek N/A
Palliative care and quality of life Christina Gerlach	Palliative care and quality of life Christina Gerlach Extremely relevant	Palliative care and quality of life Christina Gerlach Very relevant	Palliative care and quality of life Christina Gerlach Somewhat relevant	Palliative care and quality of life Christina Gerlach Not so relevant	Palliative care and quality of life Christina Gerlach Not at all relevant	Palliative care and quality of life Christina Gerlach N/A
Fundraising for patient groups and collaboration with industry Jan Geissler	Fundraising for patient groups and collaboration with industry Jan Geissler Extremely relevant	Fundraising for patient groups and collaboration with industry Jan Geissler Very relevant	Fundraising for patient groups and collaboration with industry Jan Geissler Somewhat relevant	Fundraising for patient groups and collaboration with industry Jan Geissler Not so relevant	Fundraising for patient groups and collaboration with industry Jan Geissler Not at all relevant	Fundraising for patient groups and collaboration with industry Jan Geissler N/A

Comment

Question Title

* 5. Was the content of the sessions on July 3 easy to understand?

	Extremely easy to understand	Very easy to understand	Somewhat easy to understand	Not so easy to understand	Not at all easy to understand	N/A
Developments in AL amyloidosis Monique Minnema	Developments in AL amyloidosis Monique Minnema Extremely easy to understand	Developments in AL amyloidosis Monique Minnema Very easy to understand	Developments in AL amyloidosis Monique Minnema Somewhat easy to understand	Developments in AL amyloidosis Monique Minnema Not so easy to understand	Developments in AL amyloidosis Monique Minnema Not at all easy to understand	Developments in AL amyloidosis Monique Minnema N/A
Myeloma related diseases Paolo Milani	Myeloma related diseases Paolo Milani Extremely easy to understand	Myeloma related diseases Paolo Milani Very easy to understand	Myeloma related diseases Paolo Milani Somewhat easy to understand	Myeloma related diseases Paolo Milani Not so easy to understand	Myeloma related diseases Paolo Milani Not at all easy to understand	Myeloma related diseases Paolo Milani N/A
Immunotherapy in the treatment of myeloma and AL amyloidosis María-Victoria Mateos	Immunotherapy in the treatment of myeloma and AL amyloidosis María-Victoria Mateos Extremely easy to understand	Immunotherapy in the treatment of myeloma and AL amyloidosis María-Victoria Mateos Very easy to understand	Immunotherapy in the treatment of myeloma and AL amyloidosis María-Victoria Mateos Somewhat easy to understand	Immunotherapy in the treatment of myeloma and AL amyloidosis María-Victoria Mateos Not so easy to understand	Immunotherapy in the treatment of myeloma and AL amyloidosis María-Victoria Mateos Not at all easy to understand	Immunotherapy in the treatment of myeloma and AL amyloidosis María-Victoria Mateos N/A
A clinical perspective on access in central and eastern Europe Roman Hájek	A clinical perspective on access in central and eastern Europe Roman Hájek Extremely easy to understand	A clinical perspective on access in central and eastern Europe Roman Hájek Very easy to understand	A clinical perspective on access in central and eastern Europe Roman Hájek Somewhat easy to understand	A clinical perspective on access in central and eastern Europe Roman Hájek Not so easy to understand	A clinical perspective on access in central and eastern Europe Roman Hájek Not at all easy to understand	A clinical perspective on access in central and eastern Europe Roman Hájek N/A
Palliative care and quality of life Christina Gerlach	Palliative care and quality of life Christina Gerlach Extremely easy to understand	Palliative care and quality of life Christina Gerlach Very easy to understand	Palliative care and quality of life Christina Gerlach Somewhat easy to understand	Palliative care and quality of life Christina Gerlach Not so easy to understand	Palliative care and quality of life Christina Gerlach Not at all easy to understand	Palliative care and quality of life Christina Gerlach N/A
Fundraising for patient groups and collaboration with industry Jan Geissler	Fundraising for patient groups and collaboration with industry Jan Geissler Extremely easy to understand	Fundraising for patient groups and collaboration with industry Jan Geissler Very easy to understand	Fundraising for patient groups and collaboration with industry Jan Geissler Somewhat easy to understand	Fundraising for patient groups and collaboration with industry Jan Geissler Not so easy to understand	Fundraising for patient groups and collaboration with industry Jan Geissler Not at all easy to understand	Fundraising for patient groups and collaboration with industry Jan Geissler N/A

Comment

Question Title

* 6. Tell us your thoughts on the MRD panel on Saturday, July 3? Check all that apply.

The Patient Perspective presentation was relevant

The Clinical Perspective presentation was relevant

The Regulator Perspective presentation was relevant

The information was presented in a way that was clear and easy to understand

The moderator was effective in facilitating a thoughtful discussion

The discussion was interesting and relevant to my work

Comment

Question Title

* 7. Overall, what did you think about the moderation of the sessions?

Excellent

Very good

Good

Fair

Poor

Comment

Question Title

* 8. Tell us your thoughts about the event organization. Check all that apply.

The date of the Masterclass was provided with appropriate notice

The agenda was provided with appropriate notice

The logistics and details were communicated clearly

The virtual platform was easy to use

MPE staff were helpful when I had questions or a problem

The event was organized well and ran smoothly

Comment

Post-event Feedback Survey

Question Title

* 1. I am a

Question Title

* 2. How relevant were the event sessions to you on Friday, July 2?

Question Title

* 3. Was the content of the sessions on July 2 easy to understand?

Question Title

* 4. How relevant were the event sessions to you on Saturday, July 3?

Question Title

* 5. Was the content of the sessions on July 3 easy to understand?

Question Title

* 6. Tell us your thoughts on the MRD panel on Saturday, July 3? Check all that apply.

Question Title

* 7. Overall, what did you think about the moderation of the sessions?

Question Title

* 8. Tell us your thoughts about the event organization. Check all that apply.

Question Title

* 9. What topics would you suggest for the MPE Masterclass 2022?

Question Title

* 10. Was there anything specific you liked about the Masterclass or found particularly valuable?

Question Title

* 11. Was there anything you disliked about the Masterclass and do you have suggestions for future improvements?